Mellow Hope (HTDS) Reaches a Milestone in Indonesia

   Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (www.htdsmedical.com) announced that its China-based subsidiary Shenzhen Mellow Hope has been inspected by the Indonesian Muslim Association and been issued a HALAL certificate.

The Indonesian Muslim Association inspected the Mellow Hope plant that produces the ACYW135 and A+C Meningococcal Polysaccharide vaccines. Mellow Hope plant and method of production of these vaccines met the HALAL certificate (Halal Assurance System) requirements. The Indonesian Muslim Association is well-known and regarded as the most authoritative Muslim organization in the world. The HALAL is a difficult certificate to receive, and Mellow Hope believes that there are only two companies in the world that have obtained this certificate.

With the HALAL certificate in hand, Mellow Hope believes that it will have advantage in marketing its MEVAC-ACYW and A+C in Indonesia and other Muslim countries. Mellow Hope is participating in tenders of Group ACYW135 in Indonesia and Bangladesh, and believes that the ability to acquire HALAL certificate will be a great help in securing the tenders.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Contacts: For medical and scientific dialogue inquiry only, please contact [e-mail]